Gilead Sciences Management
Management criteria checks 3/4
Gilead Sciences' CEO is Dan O'Day, appointed in Mar 2019, has a tenure of 5.33 years. total yearly compensation is $22.61M, comprised of 7.7% salary and 92.3% bonuses, including company stock and options. directly owns 0.039% of the company’s shares, worth $36.05M. The average tenure of the management team and the board of directors is 4.4 years and 6.2 years respectively.
Key information
Dan O'Day
Chief executive officer
US$22.6m
Total compensation
| CEO salary percentage | 7.7% |
| CEO tenure | 5.3yrs |
| CEO ownership | 0.04% |
| Management average tenure | 4.4yrs |
| Board average tenure | 6.2yrs |
Recent management updates
Recent updates
Gilead Records Positive Phase III Results In HIV
Jun 22Is Gilead Sciences (NASDAQ:GILD) Using Too Much Debt?
Jun 13
Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors
May 23We Think Some Shareholders May Hesitate To Increase Gilead Sciences, Inc.'s (NASDAQ:GILD) CEO Compensation
May 02Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is On The Mark
Apr 22Gilead Sciences: Some Signs Of An Impending Bottom
Apr 22Gilead Sciences: Realizing Financial Projections Is Key
Mar 20Gilead Sciences' (NASDAQ:GILD) Dividend Will Be Increased To $0.77
Mar 13Gilead's Business Development: The Good, The Bad, And The Spinning Kite Solution
Mar 01Gilead Sciences (NASDAQ:GILD) Has Announced That It Will Be Increasing Its Dividend To $0.77
Feb 28We Think Gilead Sciences' (NASDAQ:GILD) Solid Earnings Are Understated
Feb 15Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.77
Feb 13Gilead Sciences: Cheap For A Reason
Feb 10Gilead Sciences: The Sky Is Not Falling
Feb 01Does Gilead Sciences (NASDAQ:GILD) Deserve A Spot On Your Watchlist?
Jan 15CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$485m |
| Dec 31 2023 | US$23m | US$2m | US$6b |
| Sep 30 2023 | n/a | n/a | US$6b |
| Jun 30 2023 | n/a | n/a | US$5b |
| Mar 31 2023 | n/a | n/a | US$6b |
| Dec 31 2022 | US$22m | US$2m | US$5b |
| Sep 30 2022 | n/a | n/a | US$3b |
| Jun 30 2022 | n/a | n/a | US$4b |
| Mar 31 2022 | n/a | n/a | US$5b |
| Dec 31 2021 | US$19m | US$2m | US$6b |
| Sep 30 2021 | n/a | n/a | US$7b |
| Jun 30 2021 | n/a | n/a | US$5b |
| Mar 31 2021 | n/a | n/a | US$301m |
| Dec 31 2020 | US$19m | US$2m | US$123m |
| Sep 30 2020 | n/a | n/a | US$1b |
| Jun 30 2020 | n/a | n/a | -US$257m |
| Mar 31 2020 | n/a | n/a | US$5b |
| Dec 31 2019 | US$29m | US$1m | US$5b |
Compensation vs Market: Dan's total compensation ($USD22.61M) is above average for companies of similar size in the US market ($USD13.38M).
Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.
CEO
Dan O'Day (60 yo)
5.3yrs
Tenure
US$22,607,690
Compensation
Mr. Daniel P. O'Day, also known as Dan, served as Non-Executive Non-Independent Director for Galapagos NV since October 22, 2019 until March 26, 2024. He served as Member of Supervisory Board at Galapagos...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 5.3yrs | US$22.61m | 0.039% $ 36.1m | |
| Chief Financial Officer | 4.7yrs | US$8.11m | 0.011% $ 10.1m | |
| Executive VP of Corporate Affairs | 1.9yrs | US$5.27m | 0.0012% $ 1.1m | |
| Chief Commercial Officer | 5yrs | US$8.59m | 0.0097% $ 8.9m | |
| Chief Medical Officer | 4.7yrs | US$8.39m | 0.0077% $ 7.1m | |
| Senior VP | 1.3yrs | no data | 0.0027% $ 2.4m | |
| Vice President of Investor Relations | 3.5yrs | no data | no data | |
| Executive Vice President of Human Resources | 4.9yrs | no data | no data | |
| Senior Vice President of Research | 4.4yrs | no data | no data | |
| Senior Vice President of Commercial Operations of Australia | no data | no data | no data | |
| Executive Vice President of Research | 3.3yrs | no data | no data | |
| Senior Vice President & Therapeutic Area Head of Gilead Oncology | 3yrs | no data | no data |
4.4yrs
Average Tenure
58yo
Average Age
Experienced Management: GILD's management team is considered experienced (4.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 5.3yrs | US$22.61m | 0.039% $ 36.1m | |
| Lead Independent Director | 3.8yrs | US$444.92k | 0.00082% $ 750.9k | |
| Member of Scientific Advisory Board | no data | US$16.00k | no data | |
| Independent Director | 6.5yrs | US$429.92k | 0.0020% $ 1.8m | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 6.2yrs | US$414.92k | 0.0010% $ 943.2k | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 7.9yrs | US$434.92k | 0.00011% $ 100.7k | |
| Chairperson of Scientific Advisory Board | no data | no data | no data |
6.2yrs
Average Tenure
71yo
Average Age
Experienced Board: GILD's board of directors are considered experienced (6.2 years average tenure).